Meletios Athanasios Dimopoulos

2 months ago | nature.com | Katja Weisel |Maria-Victoria Mateos |Meletios Athanasios Dimopoulos

AbstractPatients with relapsed/refractory multiple myeloma (RRMM) have a poor prognosis and a need remains for novel effective therapies. Belantamab mafodotin, an anti–B-cell maturation antigen antibody-drug conjugate, was granted accelerated/conditional approval for patients with RRMM who have received at least 4 prior lines of therapy, based on response rates observed in DREAMM-1/DREAMM-2.